Evidence map›Paper›PMID 41236484›Full record

ArticleFuture oncology (London, England)2025

Osimertinib before and after chemoradiotherapy for unresectable stage III EGFR-mutated NSCLC: NEOLA Trial Protocol.

Jacqueline V Aredo, Nir Peled, Edurne Arriola, Heather Wakelee, Myung-Ju Ahn, Margriet H Kwint, Rosemary Taylor, Toon van der Gronde, Feruza Nasirova, Ming Chen

Registry-linked trialAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Future oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06194448 (A Phase II, Open-label, Single-arm Study of Osimertinib as Induction Therapy Prior to CRT and Maintenance Osimertinib in Patients With Epidermal Growth Factor Receptor), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06194448 phase2active not recruitingnot on this map

A Phase II, Open-label, Single-arm Study of Osimertinib as Induction Therapy Prior to CRT and Maintenance Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive, Stage III, Unresectable Non-small Cell Lung Cancer (NEOLA)

TypeinterventionalSponsorAstraZenecaRan2024 to 2027Enrolled76ConditionsLung CancerArmsOsimertinib, Cisplatin or Carboplatin, Pemetrexed or Paclitaxel, Radiation
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jacqueline V AredoDepartment of Medicine, Division of Oncology, Stanford University School of Medicine and Stanford Cancer Institute, Stanford, CA, USA.
Nir PeledHelmsely Cancer Center, Shaare Zedek Medical Center, Jerusalem, Israel.
Edurne ArriolaDepartment of Medical Oncology, Hospital del Mar-CIBERONC, Barcelona, Spain.
Heather WakeleeDepartment of Medicine, Division of Oncology, Stanford University School of Medicine and Stanford Cancer Institute, Stanford, CA, USA.
Myung-Ju AhnDivision of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Margriet H KwintMedical Affairs, AstraZeneca, The Hague, The Netherlands.
Rosemary TaylorBiometrics, Late-Stage Development, Oncology R&D, AstraZeneca, Macclesfield, UK.
Toon van der GrondeLate-Stage Development, Oncology R&D, AstraZeneca, New York, NY, USA.
Feruza NasirovaGlobal Medical Affairs, AstraZeneca, Cambridge, UK.
Ming ChenDepartment of Radiotherapy, Sun Yat-Sen University Cancer Center, Guangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CLINICAL

trial registrationClinicalTrials.gov identifier is NCT06194448 (date of registration 5 January 2024).

Indexed as

AcrylamidesAniline CompoundsCarcinoma, Non-Small-Cell LungChemoradiotherapyLung NeoplasmsErbB ReceptorsHumansIndolesMutationNeoplasm StagingProtein Kinase InhibitorsPyrimidinesTreatment OutcomeAcrylamidesAniline CompoundsEGFR protein, humanErbB ReceptorsIndolesosimertinibProtein Kinase InhibitorsPyrimidineschemoradiotherapyEGFR mutationEGFR-tyrosine kinase inhibitorosimertinibstage III NSCLCunresectable

Identifiers

PMID41236484
PMCPMC12688264

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.